What is SelectION?
SelectION Therapeutics operates as a clinical-stage biopharmaceutical entity dedicated to the advancement of novel treatments for T cell-mediated autoimmune disorders. The company's primary asset, si-544, represents a first-in-class Kv1.3 blocker designed to selectively deactivate pathogenic T cells. This mechanism of action is engineered to preserve healthy immune function while addressing the underlying drivers of conditions such as psoriasis, rheumatoid arthritis, and multiple sclerosis. By focusing on durable disease modification, SelectION is positioning itself as a pivotal player in the immunology sector, aiming to shift the standard of care from symptom management to root-cause intervention.
The company's strategic focus on high-impact therapeutic areas reflects a sophisticated approach to drug development. By leveraging proprietary technology to modulate immune responses, SelectION seeks to provide patients with improved quality of life and long-term remission potential, distinguishing its pipeline in a crowded market of autoimmune therapeutics.
How much funding has SelectION raised?
SelectION has raised a total of $46.4M across 2 funding rounds:
Series A
$41M
Private Equity
$5.4M
Series A (2019): $41M with participation from SDL Ventures and Gloabl Source Ventures
Private Equity (2025): $5.4M, investors not publicly disclosed
Key Investors in SelectION
SDL Ventures
An investment firm founded by industry veterans that focuses on supporting technology-driven startups and high-growth ventures.
Gloabl Source Ventures
Undisclosed investor participating in the funding round.
What's next for SelectION?
With the recent influx of capital, SelectION Therapeutics is well-positioned to accelerate its clinical development programs and expand its research capabilities. The company will likely prioritize the advancement of si-544 through critical trial phases, aiming to validate its efficacy and safety profile in human subjects. Furthermore, the firm is expected to leverage this financial runway to strengthen its intellectual property portfolio and potentially explore additional indications for its Kv1.3 blocker platform. As the company transitions into more advanced clinical stages, the focus will shift toward regulatory milestones and strategic partnerships that could facilitate the eventual commercialization of its lead assets. This phase of growth is essential for establishing SelectION as a leader in the next generation of autoimmune disease management.
See full SelectION company page
